2012 Fiscal Year Final Research Report
Development of oncolytic adenovirus as a new therapeutic agent for treating human malignant mesothelioma
| Project/Area Number |
22590370
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | Hyogo Medical University |
|---|
Principal Investigator |
KUBO Shuji 兵庫医科大学, 医学部, 准教授 (10441320)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OKAMURA Haruki 兵庫医科大学, 医学部, 教授 (60111043)
TERADA Nobuyuki 兵庫医科大学, 医学部, 教授 (50150339)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | 腫瘍 / 悪性中皮腫 |
|---|
| Research Abstract |
Our new oncolytic adenovirus, in which adenoviral replication and HSV-TK suicide gene expression was transcriptional regulated by tumor-specific midkine promoter, achieved:1) tumor-specific lytic spread of the virus, 2) anti-tumor effect in subcutaneous, intrathoracic, and intraperitoneal mesothelioma mouse models, and 3) enhanced anti-tumor effect by suicide gene activation. The midkine-promoter regulated oncolytic virus represents a promising general strategy for oncolytic virotherapy of cancers withupregulated midkine expression, including malignant mesothelioma.
|
